about
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trialHearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonismThe outcome and cost-effectiveness of nurse-led care in people with rheumatoid arthritis: a multicentre randomised controlled trial2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisGenome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controlsTRPC channel activation by extracellular thioredoxinMinocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndromeWhen a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritisBone mineral density improvement in spondyloarthropathy after treatment with etanerceptEfficacy of infliximab on MRI-determined bone oedema in psoriatic arthritisUltrasonography for rheumatologists: the development of specific competency based educational outcomesInterleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopeniaIs localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for preventionThe role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature reviewBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisValue of ultrasound in rheumatologic diseases.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateNonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementEULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteriaUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk lociSubclinical vasculitis in polymyalgia rheumaticaInfliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupOptimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow.Is it time to revisit the role of ultrasound in rheumatoid arthritis management?Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.Skin imaging in systemic sclerosis.Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical diseaseMultiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.The impact of rheumatoid arthritis on foot function in the early stages of disease: a clinical case series.The treatment of lupus with cyclosporin A.Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.Variability in depression prevalence in early rheumatoid arthritis: a comparison of the CES-D and HAD-D Scales.
P50
Q19862843-83CD2BB3-5485-4687-94EF-3269E2574996Q24307718-6D3418BA-788C-4A7A-8793-855F19966148Q24564701-79D0B66F-D9AD-4B30-BF13-A66F5432D07BQ24603648-9CF746F8-A11F-41B3-81A9-C31C76C062BEQ24628710-4FEFFB63-89B3-488A-A2B1-C01CFFAE9226Q24650851-96772853-203A-4A18-86B7-635BCE6C5552Q24655734-22570B5F-3B86-4AC9-9096-668BBC727408Q24673434-AA0CC169-7194-4A6C-88AD-58908F946C99Q24673687-A3F19CBB-9E87-4E10-90E7-89894ED599AAQ24674266-62A085E1-36DE-4968-AEB2-08FE09150A9CQ24674877-F6F7D00A-9C97-42B9-948B-C95CFA363004Q24675328-B055532B-E0F1-458D-9D50-0448140196E1Q24798777-2CDC4675-12CA-40B9-A896-C35E00F7A673Q26783640-749F1946-70DC-4A78-A91C-1E6CFC807103Q26786206-BCB1BFE3-921F-4DF4-92DA-86BAE5E22345Q26852235-A44548B4-4D33-4D9A-B616-28DB2CE7D29BQ26853249-F3E0074D-9659-4858-BC0F-FA133414CB5FQ26859134-4E88FB64-E0A1-460B-ADBE-020996F3BCDDQ26864640-16950A49-8059-483F-9EC1-929F0D849F79Q27021115-23CD27ED-31FB-4FBB-97B8-5E2C7B45C211Q27026582-4A300CEF-1CBC-420A-ADE4-60524E17A861Q27691388-5A249A45-9895-4EBB-BB0C-5D03E5140490Q28281906-D84318E9-6244-4C18-BF8B-B97374098645Q28361777-19D8403C-3EDE-4C9F-A717-0C0476122816Q29616063-B067F275-97E5-42CB-ABF2-C81A18D42483Q30159650-5555AD5C-CC2E-498A-BC5D-5D0669A09836Q30240088-E4B2DCA0-A32F-471B-88AE-AAC0E6DF13B2Q30249836-2A555146-5ACA-41F4-AC83-954313FBA646Q30372810-88BAAC35-B0E4-4DC0-8B8F-DE6CD85B85DCQ30499234-717275f8-494d-7934-3f59-e4d856a0889fQ30571623-50F0826A-E4F8-4D1E-B1CA-D61B76FA9B92Q30680371-F82D5488-2DBC-491A-8546-27B0ABF3E526Q30826279-DB4622F1-3A1A-4005-9707-4E73B99D1298Q30887400-483ACC9C-1B14-40D2-AE97-0073385DF910Q30986148-C98A9AC8-0E15-450F-87BA-B569ACDE0EA2Q33267392-46712148-ED23-4F68-9E4C-D32B561DF73CQ33336953-ADE2EEB1-A615-4E58-A94E-2732B1188189Q33369384-2FB11A62-2252-43FA-8B32-B71CA922565BQ33369386-3367D245-E4AA-4F13-A701-F4AFB7ACDCB2Q33406652-424c846c-4b12-af61-4a64-d241f40557e8
P50
description
Professor of Rheumatology
@en
Professor of Rheumatology
@en-gb
ollamh le réamaiteolaíocht
@ga
onderzoeker
@nl
name
Paul Emery
@ast
Paul Emery
@cy
Paul Emery
@da
Paul Emery
@en
Paul Emery
@en-gb
Paul Emery
@es
Paul Emery
@fr
Paul Emery
@ga
Paul Emery
@it
Paul Emery
@nl
type
label
Paul Emery
@ast
Paul Emery
@cy
Paul Emery
@da
Paul Emery
@en
Paul Emery
@en-gb
Paul Emery
@es
Paul Emery
@fr
Paul Emery
@ga
Paul Emery
@it
Paul Emery
@nl
altLabel
P Emery
@cy
P Emery
@en
P Emery
@en-gb
prefLabel
Paul Emery
@ast
Paul Emery
@cy
Paul Emery
@da
Paul Emery
@en
Paul Emery
@en-gb
Paul Emery
@es
Paul Emery
@fr
Paul Emery
@ga
Paul Emery
@it
Paul Emery
@nl
P1006
P214
P244
P6366
P1006
P106
P1153
7201777137
P2031
1987-01-01T00:00:00Z
P2038
Paul_Emery
P21
P213
0000 0000 3232 4270
P214
P244
n2001127725
P31
P4012
P6178
01175471513.15
P6366
2144675545